MCID: ESS001
MIFTS: 58

Essential Tremor

Categories: Genetic diseases, Neuronal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Essential Tremor

MalaCards integrated aliases for Essential Tremor:

Name: Essential Tremor 12 53 25 54 37 29 55 6 44 15 73
Hereditary Essential Tremor 53 25 6
Benign Essential Tremor 12 53 25
Essential Tremor, Susceptibility to 13 6
Familial Tremor 25 73
Benign Essential Tremor Syndrome 76
Tremor, Hereditary Essential, 1 53
Essential Hereditary Tremor 12
Tremor Hereditary Essential 76
Familial Essential Tremor 53
Presenile Tremor Syndrome 53
Shaky Hand Syndrome 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4990
ICD10 33 G25.0
MeSH 44 D020329
SNOMED-CT 68 632009
KEGG 37 H01577

Summaries for Essential Tremor

NINDS : 54 Tremor is an unintentional, somewhat rhythmic, muscle movement involving to-and-fro movements (oscillations) of one or more parts of the body. Essential tremor (previously called benign essential tremor) is the most common form of abnormal tremor. (In some people, tremor is a symptom of a neurological disorder or appears as a side effect of certain drugs.)  Although it may be mild and nonprogressive in some people, in others the tremor is slowly progressive, starting on one side of the body but eventually affecting both sides. Hand tremor is most common but the head, arms, voice, tongue, legs, and trunk may also be involved. Hand tremor may cause problems with purposeful movements such as eating, writing, sewing, or shaving. Head tremor may be seen as a "yes-yes" or "no-no" motion. Essential tremor may be accompanied by mild gait disturbance. Heightened emotion, stress, fever, physical exhaustion, or low blood sugar may trigger tremors or increase their severity. There may be mild degeneration in the certain parts of the cerebellum in persons with essential tremor.  Onset is most common after age 40, although symptoms can appear at any age. Children of a parent who has essential tremor have up to a 50 percent chance of inheriting the condition. Essential tremor is not associated with any known pathology.

MalaCards based summary : Essential Tremor, also known as hereditary essential tremor, is related to movement disease and tremor, and has symptoms including tremor, action tremor and essential and other specified forms of tremor. An important gene associated with Essential Tremor is ETM2 (Essential Tremor 2), and among its related pathways/superpathways are Neuroscience and Parkinsons Disease Pathway. The drugs Dopamine and Propranolol have been mentioned in the context of this disorder. Affiliated tissues include brain, cerebellum and thalamus, and related phenotype is nervous system.

Disease Ontology : 12 A movement disorder that causes involuntary tremors, especially in the hands. It occurs alone without other neurological signs and symptoms.

Genetics Home Reference : 25 Essential tremor is a movement disorder that causes involuntary, rhythmic shaking (tremor), especially in the hands. It is distinguished from tremor that results from other disorders or known causes, such as Parkinson disease or head trauma. Essential tremor usually occurs alone, without other neurological signs or symptoms. However, some experts think that essential tremor can include additional features, such as mild balance problems.

NIH Rare Diseases : 53 Essential tremor is the most common movement disorder.  It is characterized by involuntary and rhythmic shaking (tremor), especially in the hands, without any other signs or symptoms. It is distinguished from tremor that results from other disorders or known causes, such as tremors seen with Parkinson disease or head trauma. Most cases of essential tremor are hereditary. There are five forms of essential tremor that are based on different genetic causes. Several genes as well as lifestyle and environmental factors likely play a role in a person's risk of developing this complex condition. In mild cases, treatment may not be necessary. In cases where symptoms interfere with daily living, medications may help to relieve symptoms.     

Wikipedia : 76 Essential tremor (ET, also referred to as benign tremor, familial tremor, or idiopathic tremor) is a... more...

Related Diseases for Essential Tremor

Diseases in the Tremor family:

Tremor, Hereditary Essential, 1 Tremor, Hereditary Essential, 2
Tremor, Hereditary Essential, 3 Tremor, Hereditary Essential, 4
Tremor, Hereditary Essential, 5 Essential Tremor

Diseases related to Essential Tremor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 78)
# Related Disease Score Top Affiliating Genes
1 movement disease 31.6 DRD3 FMR1 LRRK2 PRKN SLC6A3 SNCA
2 tremor 31.4 CHCHD2 DNAJC13 DRD3 FMR1 FUS HTRA2
3 restless legs syndrome 30.2 DRD3 PRKN SLC6A3 SNCA
4 multiple system atrophy 1 30.1 LRRK2 PRKN SLC6A3 SNCA
5 dementia 30.0 FUS LRRK2 PRKN SLC6A3 SNCA
6 supranuclear palsy, progressive, 1 29.8 LRRK2 PRKN SLC6A3 SNCA
7 rem sleep behavior disorder 29.8 LRRK2 SLC6A3 SNCA
8 early-onset parkinson's disease 29.7 LRRK2 PRKN SNCA
9 parkinson disease, late-onset 29.6 CHCHD2 DNAJC13 DRD3 HTRA2 LINGO1 LRRK2
10 tremor, hereditary essential, and idiopathic normal pressure hydrocephalus 12.4
11 sensorineural hearing loss-early graying-essential tremor syndrome 12.2
12 tremor, hereditary essential, 1 11.9
13 tremor, hereditary essential, 5 11.7
14 tremor, hereditary essential, 2 11.5
15 tremor, nystagmus, and duodenal ulcer 11.2
16 tremor, hereditary essential, 3 11.2
17 tremor, hereditary essential, 4 11.2
18 mental retardation, autosomal recessive 48 11.2
19 nephronophthisis-like nephropathy 1 11.0
20 x-linked dystonia-parkinsonism/lubag 11.0
21 deep brain stimulation for movement disorders 11.0
22 dystonia 10.5
23 cervical dystonia 10.3
24 alzheimer disease 10.2
25 depression 10.2
26 postencephalitic parkinson disease 10.1 LRRK2 SNCA
27 hereditary late-onset parkinson disease 10.1 DNAJC13 LRRK2 SNCA
28 dysautonomia 10.1 PRKN SNCA
29 bell's palsy 10.0 HS1BP3 PRKN
30 torticollis 10.0
31 anxiety 10.0
32 benign shuddering attacks 10.0
33 parkinson disease 15, autosomal recessive early-onset 10.0 PRKN SNCA
34 parkinson disease 10 10.0 LRRK2 PRKN SNCA
35 toxic encephalopathy 10.0 SLC1A2 SLC6A3 SNCA
36 parkinson disease 3, autosomal dominant 10.0 LRRK2 PRKN SNCA
37 striatonigral degeneration 10.0 SLC6A3 SNCA
38 pathological gambling 10.0 DRD3 SLC6A3
39 motor neuron disease 10.0 FUS SLC1A2 SNCA
40 hypogonadotropic hypogonadism 10.0
41 sarcoma 10.0
42 social phobia 10.0
43 disease of mental health 9.9 DRD3 FMR1 SLC6A3 SNCA
44 synucleinopathy 9.9 LRRK2 PRKN SLC6A3 SNCA
45 dementia, lewy body 9.9 LRRK2 PRKN SLC6A3 SNCA
46 parkinson disease 2, autosomal recessive juvenile 9.9 HTRA2 LRRK2 PRKN SNCA
47 nervous system disease 9.9 LRRK2 PRKN SLC6A3 SNCA
48 central nervous system disease 9.9 LRRK2 PRKN SLC6A3 SNCA
49 amyotrophic lateral sclerosis 1 9.8
50 coumarin resistance 9.8

Graphical network of the top 20 diseases related to Essential Tremor:



Diseases related to Essential Tremor

Symptoms & Phenotypes for Essential Tremor

UMLS symptoms related to Essential Tremor:


tremor, action tremor, essential and other specified forms of tremor, senile tremor, physiological tremor

MGI Mouse Phenotypes related to Essential Tremor:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.32 DRD3 FMR1 HTRA2 LINGO1 LRRK2 PRKN

Drugs & Therapeutics for Essential Tremor

Drugs for Essential Tremor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 90)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3 51-61-6, 62-31-7 681
2
Propranolol Approved, Investigational Phase 4,Not Applicable 525-66-6 4946
3
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Not Applicable 51-84-3 187
4
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
5
Memantine Approved, Investigational Phase 4 19982-08-2 4054
6
Iodine Approved, Investigational Phase 4 7553-56-2 807
7 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
8 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
9 Dopamine Agents Phase 4,Phase 3
10 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
11 Vasodilator Agents Phase 4,Not Applicable
12 Adrenergic beta-Antagonists Phase 4,Not Applicable
13 Acetylcholine Release Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
14 Adrenergic Antagonists Phase 4,Not Applicable
15 Anti-Arrhythmia Agents Phase 4,Not Applicable
16 Cholinergic Agents Phase 4,Phase 3,Phase 2,Not Applicable
17 Antihypertensive Agents Phase 4,Not Applicable
18 Adrenergic Agents Phase 4,Phase 2,Phase 3,Not Applicable
19 Botulinum Toxins Phase 4,Phase 3,Phase 2,Not Applicable
20 Tranquilizing Agents Phase 4
21 Calcium, Dietary Phase 4,Phase 2
22 Psychotropic Drugs Phase 4
23 Anti-Anxiety Agents Phase 4
24 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 calcium channel blockers Phase 4,Phase 2
26 Analgesics Phase 4,Phase 2,Phase 3,Not Applicable
27 Excitatory Amino Acid Antagonists Phase 4
28 Antiparkinson Agents Phase 4,Phase 3
29 Excitatory Amino Acids Phase 4
30 Pharmaceutical Solutions Phase 4,Phase 2
31 Calamus Phase 4
32 cadexomer iodine Phase 4
33
Cocaine Approved, Illicit Phase 3 50-36-2 5760 446220
34
Topiramate Approved Phase 3 97240-79-4 5284627
35
Dexmedetomidine Approved, Vet_approved Phase 2, Phase 3,Not Applicable 113775-47-6 68602 5311068
36 abobotulinumtoxinA Phase 3,Phase 2,Not Applicable
37 Botulinum Toxins, Type A Phase 3,Phase 2,Not Applicable
38 onabotulinumtoxinA Phase 3,Phase 2,Not Applicable
39 Vasoconstrictor Agents Phase 3
40 Anesthetics, Local Phase 3,Not Applicable
41 Anesthetics Phase 3,Phase 2,Not Applicable
42 Dopamine Uptake Inhibitors Phase 3
43 Neurotransmitter Uptake Inhibitors Phase 3
44 Anti-Obesity Agents Phase 3
45 Protective Agents Phase 3,Phase 2,Phase 1,Not Applicable
46 Neuroprotective Agents Phase 3,Phase 1,Phase 2
47 Antioxidants Phase 3,Phase 2,Not Applicable
48 Adrenergic alpha-Agonists Phase 2, Phase 3,Not Applicable
49 Hypnotics and Sedatives Phase 2, Phase 3,Not Applicable
50 Adrenergic Agonists Phase 2, Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 156)
# Name Status NCT ID Phase Drugs
1 Pregabalin in the Treatment of Essential Tremor Completed NCT00646451 Phase 4 pregabalin;placebo capsules
2 A Pilot Clinical Trial Of Memantine for Essential Tremor Completed NCT00439699 Phase 4 Memantine
3 Pregabalin (Lyrica) for the Treatment of Essential Tremor Completed NCT00584376 Phase 4 Pregabalin;Placebo
4 Propranolol and Botulinum Toxin for Essential Vocal Tremor Completed NCT02111369 Phase 4 Propranolol
5 RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR) Completed NCT00998660 Phase 4
6 A Study to Assess Changes in Clinical Management After DaTSCAN Imaging of Subjects With Clinically Uncertain Parkinsonism or an Illness With Similar Symptoms Completed NCT00382967 Phase 4
7 Atlas Predicted DBS Settings in Essential Tremor Enrolling by invitation NCT02678429 Phase 4
8 DaTSCAN Imaging in Aging and Neurodegenerative Disease Enrolling by invitation NCT01453127 Phase 4 I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)
9 Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor Unknown status NCT02555982 Phase 3 BOTOX ® 200 Unités;Placebo
10 Two Separate But Identical Studies Evaluating the Safety and Efficacy of ALTROPANE® in the Use of SPECT Imaging for Upper Extremity Tremor Unknown status NCT00724906 Phase 3 123 I - ALTROPANE®
11 Novel Therapies for Essential Tremor Completed NCT00018564 Phase 3 treatments for essential tremor
12 A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in Treating Tremor of Unknown Cause. Completed NCT00236496 Phase 3 topiramate
13 Efficacy and Safety of F-18 FPCIT PET in Parkinson's Disease and Essential Tremor Patients Completed NCT00468078 Phase 3 F-18 FPCIT
14 CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients Not yet recruiting NCT03769298 Phase 2, Phase 3 Envarsus XR
15 Pre-lemniscal Radiation Deep Brain Stimulation for ET Terminated NCT00634478 Phase 2, Phase 3
16 Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor Withdrawn NCT01441284 Phase 3 pramipexole;placebo
17 Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation Withdrawn NCT00608231 Phase 2, Phase 3 Dexmedetomidine Hydrochloride Infusion;Normal Saline
18 An Efficacy/Safety Study of Perampanel for Reducing Essential Tremor Unknown status NCT02668146 Phase 2 Perampanel;Placebo
19 Deep Brain Stimulation for Voice Tremor: Left, Right, or Both Hemispheres? Unknown status NCT02960243 Phase 1, Phase 2
20 Randomised Crossover Trial of Deep Brain Stimulation of Differential Posterior Subthalamic Area Regions in Parkinson's Disease and Tremor Unknown status NCT01945567 Phase 2
21 Deep Brain Frameless Radiosurgery for Drug Resistant Invalidating Tremor. Dose Escalation Pilot Study Unknown status NCT02585583 Phase 2
22 A Phase 2 RCT Study of CX-8998 for Essential Tremor Completed NCT03101241 Phase 2 CX-8998;Placebo
23 A Pilot Efficacy and Safety Study of ST101 in Essential Tremor Completed NCT01332695 Phase 2 ST101;Placebo
24 A Safety/Efficacy Trial of Zonisamide for Essential Tremor Completed NCT00223743 Phase 2 Zonisamide
25 A Study to Evaluate SAGE-217 in Subjects With Essential Tremor Completed NCT02978781 Phase 2 SAGE-217;Placebo
26 Multiple-dose,Double-blind,Placebo-controlled Study of Sodium Oxybate in Patients With Essential Tremor Completed NCT00598078 Phase 2 Sodium Oxybate;Sodium Oxybate
27 Evaluate SAGE-547 in Patients With Essential Tremor Completed NCT02277106 Phase 2 SAGE-547;Placebo
28 A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential Tremor Completed NCT00524056 Phase 2 Carisbamate;Placebo
29 Double-Blind, Placebo Controlled Pilot Study of Octanoic Acid in Essential Tremor Completed NCT00848172 Phase 1, Phase 2 Octanoic Acid;Placebo
30 Efficacy of Levetiracetam in Essential Tremor Completed NCT00620165 Phase 1, Phase 2 levetiracetam;placebo
31 Octanol to Treat Essential Tremor Completed NCT00080366 Phase 2 1-Octanol
32 Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor Completed NCT00102596 Phase 2 1-Octanol
33 Botulinum Toxin A to Treat Arm Tremor Completed NCT02207946 Phase 2 IncobotulinumtoxinA;Placebo
34 Effects of Octanoic Acid for Treatment of Essential Voice Tremor Completed NCT01864525 Phase 1, Phase 2 Octanoic acid;Inactive capsule
35 Trial of Cannabis for Essential Tremor Recruiting NCT03805750 Phase 1, Phase 2 CBD/THC;Placebo oral capsule
36 tSMS in Essential Tremor Recruiting NCT03780426 Phase 2
37 Kinematic-based BoNT-A Injections for Bilateral ET Active, not recruiting NCT02551848 Phase 2 Botulinum toxin type A
38 Use of Kinematic Assessment of Hand Tremor Pre- and Post- Treatment With Botulinum Toxin Type A in Essential Tremor and Parkinson Disease Active, not recruiting NCT02427646 Phase 2 IncobotulinumtoxinA
39 Kinematic-based BoNT-A Bilateral Upper Limb PD Therapy Active, not recruiting NCT02668497 Phase 2 Botulinum Toxin Type A
40 A Clinical Study to Evaluate CAD-1883 in Essential Tremor Not yet recruiting NCT03688685 Phase 2 CAD-1883
41 T2000 in Essential Tremor - Open Label Continuation Terminated NCT00655278 Phase 2 T2000
42 A Study of T2000 in Essential Tremor Terminated NCT00321087 Phase 2 T2000;T2000;T2000
43 Thalamic Deep Brain Stimulation for Spasmodic Dysphonia- DEBUSSY Trial Unknown status NCT02558634 Phase 1
44 Octanoic Acid for Essential Tremor Completed NCT01468948 Phase 1 Octanoic Acid
45 ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential Tremor Completed NCT02037217 Phase 1
46 ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential Tremor Completed NCT01304758 Phase 1
47 1-Octanol to Treat Essential Tremor Completed NCT00016679 Phase 1 1-Octanol
48 1-Octanol to Treat Essential Tremor Completed NCT00001986 Phase 1 1-Octanol
49 Magnetic Resonance (MR) Guided Functional Ultrasound-Neurosurgery for Movement Disorders Completed NCT01698450 Phase 1
50 Experimental Therapeutics in Essential Tremor Using Cerebellar Transcranial Direct Current Stimulation Unknown status NCT02052271 Not Applicable

Search NIH Clinical Center for Essential Tremor

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: essential tremor

Genetic Tests for Essential Tremor

Genetic tests related to Essential Tremor:

# Genetic test Affiliating Genes
1 Essential Tremor 29

Anatomical Context for Essential Tremor

MalaCards organs/tissues related to Essential Tremor:

41
Brain, Cerebellum, Thalamus, Tongue, Cortex, Testes, Spinal Cord

Publications for Essential Tremor

Articles related to Essential Tremor:

(show top 50) (show all 1160)
# Title Authors Year
1
Quantitative Assessment of Pathological Tau Burden in Essential Tremor: A Postmortem Study. ( 30476290 )
2019
2
Caffeine Consumption in First-Degree Relatives of Essential Tremor Cases: Evidence of Dietary Modification Before Disease Onset. ( 29953981 )
2018
3
Deep Brain Stimulation Management of Essential Tremor with Dystonic Features. ( 29971197 )
2018
4
Objective predictors of 'early tolerance' to ventral intermediate nucleus of thalamus deep brain stimulation in essential tremor patients. ( 29908405 )
2018
5
Unilateral Left Deep Brain Stimulation of the Caudal Zona Incerta Is Equally Effective on Voice Tremor as Bilateral Stimulation: Evidence from 7 Patients with Essential Tremor. ( 29975951 )
2018
6
The effects of Thalamic Deep Brain Stimulation on speech dynamics in patients with Essential Tremor: An articulographic study. ( 29360867 )
2018
7
Magnetic resonance-guided focused ultrasound thalamotomy for tremor: a report of 30 Parkinson's disease and essential tremor cases. ( 28298022 )
2018
8
White matter measures correlate with essential tremor severity-A pilot diffusion tensor imaging study. ( 29964316 )
2018
9
Clinical response to Vim's thalamic stereotactic radiosurgery for essential tremor is associated with distinctive functional connectivity patterns. ( 29335882 )
2018
10
Comparative Burden of Subclinical Tremor in a Cohort of Normal Individuals Stratified by Familial Risk for Essential Tremor. ( 29339654 )
2018
11
A method for pre-operative single-subject thalamic segmentation based on probabilistic tractography for essential tremor deep brain stimulation. ( 29307012 )
2018
12
Essential tremor: "Plus" or "Minus". Perhaps now is the time to adopt the term "the essential tremors". ( 29937098 )
2018
13
Hand Tremor Questionnaire: A Useful Screening Tool for Differentiating Patients with Hand Tremor between Parkinson's Disease and Essential Tremor. ( 29971978 )
2018
14
Dysgeusia in deep brain stimulation for essential tremor. ( 29402567 )
2018
15
Pretherapeutic motor thalamus resting-state functional connectivity with visual areas predicts tremor arrest after thalamotomy for essential tremor: tracing the cerebello-thalamo-visuo-motor network. ( 29920392 )
2018
16
Clinical, electrophysiological, and imaging study in essential tremor-Parkinson's disease syndrome. ( 29885986 )
2018
17
Letter to the Editor. Magnetic resonance-guided focused ultrasound and essential tremor. ( 29961391 )
2018
18
Long Trace Eyeblink Conditioning Is Largely Preserved in Essential Tremor. ( 29916048 )
2018
19
Serum concentration and clinical significance of brain-derived neurotrophic factor in patients with Parkinson's disease or essential tremor. ( 29350074 )
2018
20
Shaky and unsteady: Dynamic posturography in essential tremor. ( 29406890 )
2018
21
Effects on cognition and quality of life with unilateral magnetic resonance-guided focused ultrasound thalamotomy for essential tremor. ( 29385928 )
2018
22
Thalamic Deep Brain Stimulation Salvages Failed Focused Ultrasound Thalamotomy for Essential Tremor: A Case Report. ( 29433124 )
2018
23
A Novel Posture for Better Differentiation Between Parkinson's Tremor and Essential Tremor. ( 29867328 )
2018
24
Association study of essential tremor genetic loci in Parkinson'sA disease. ( 29398123 )
2018
25
Inferior Olivary nucleus degeneration does not lessen tremor in essential tremor. ( 29372062 )
2018
26
Essential tremor. ( 29325613 )
2018
27
DBS of the PSA and the VIM in essential tremor: A randomized, double-blind, crossover trial. ( 29970404 )
2018
28
A meta-analysis of outcomes and complications of magnetic resonance-guided focused ultrasound in the treatment of essential tremor. ( 29385917 )
2018
29
Conditions Associated with Essential Tremor in Veterans: A Potential Role for Chronic Stress. ( 29971194 )
2018
30
Validating the targets for neurostimulation in essential tremor. ( 29970402 )
2018
31
Pretherapeutic Functional Imaging Allows Prediction of Head Tremor Arrest After Thalamotomy for Essential Tremor: The Role of Altered Interconnectivity Between Thalamolimbic and Supplementary Motor Circuits. ( 29410136 )
2018
32
Knowledge about Essential Tremor: A Study of Essential Tremor Families. ( 29434571 )
2018
33
Corrigendum: Digitizing Tablet and Fahn-Tolosa-MarA-n Ratings of Archimedes Spirals have Comparable Minimum Detectable Change in Essential Tremor. ( 29971202 )
2018
34
Uric acid level may not be reduced in essential tremor. ( 29936882 )
2018
35
Essential tremor and the cerebellum. ( 29891062 )
2018
36
Double target DBS for essential tremor: 8-contact lead for cZI and vim aligned in the same trajectory. ( 29438045 )
2018
37
Preliminary experience with a transcranial magnetic resonance-guided focused ultrasound surgery system integrated with a 1.5-T MRI unit in a series of patients with essential tremor and Parkinson's disease. ( 29385927 )
2018
38
Somatosensory temporal discrimination in Parkinson's disease, dystonia and essential tremor: Pathophysiological and clinical implications. ( 29981960 )
2018
39
Differential effects of propranolol on head and upper limb tremor in patients with essential tremor and dystonia. ( 30209649 )
2018
40
Prediction of Electrode Contacts for Clinically Effective Deep Brain Stimulation in Essential Tremor. ( 30269142 )
2018
41
Targeting the hot spot in a patient with essential tremor and Parkinson's disease: Tractography matters. ( 30286441 )
2018
42
Magnetic resonance-guided focused ultrasound thalamotomy for treatment of essential tremor: A 2-year outcome study. ( 30288794 )
2018
43
Long-term effects of unilateral deep brain stimulation on voice tremor in patients with essential tremor. ( 30297208 )
2018
44
Evaluating Mild Cognitive Impairment in Essential Tremor: How Many and Which Neuropsychological Tests? ( 30303051 )
2018
45
Focused Ultrasound Thalamotomy and Other Interventions for Medication-Refractory Essential Tremor: An Indirect Comparison of Short-Term Impact on Health-Related Quality of Life. ( 30314617 )
2018
46
Absence of Mutation Enrichment for Genes Phylogenetically Conserved in the Olivocerebellar Motor Circuitry in a Cohort of Canadian Essential Tremor Cases. ( 30315477 )
2018
47
Perampanel, a new hope for Essential tremor: An open label trial. ( 30318448 )
2018
48
Outcomes from stereotactic surgery for essential tremor. ( 30337440 )
2018
49
Cortical dynamics within and between parietal and motor cortex in essential tremor. ( 30345712 )
2018
50
Ventral Intermediate Nucleus Versus Zona Incerta Region Deep Brain Stimulation in Essential Tremor. ( 30363386 )
2018

Variations for Essential Tremor

ClinVar genetic disease variations for Essential Tremor:

6 (show all 44)
# Gene Variation Type Significance SNP ID Assembly Location
1 DRD3 NM_000796.5(DRD3): c.25G> A (p.Gly9Ser) single nucleotide variant Likely benign rs6280 GRCh37 Chromosome 3, 113890815: 113890815
2 DRD3 NM_000796.5(DRD3): c.25G> A (p.Gly9Ser) single nucleotide variant Likely benign rs6280 GRCh38 Chromosome 3, 114171968: 114171968
3 DNAJC13 NM_015268.3(DNAJC13): c.2564A> G (p.Asn855Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs387907571 GRCh37 Chromosome 3, 132196839: 132196839
4 DNAJC13 NM_015268.3(DNAJC13): c.2564A> G (p.Asn855Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs387907571 GRCh38 Chromosome 3, 132477995: 132477995
5 DRD3 NM_000796.5(DRD3): c.691T> A (p.Cys231Ser) single nucleotide variant Uncertain significance rs150042478 GRCh38 Chromosome 3, 114139532: 114139532
6 DRD3 NM_000796.5(DRD3): c.691T> A (p.Cys231Ser) single nucleotide variant Uncertain significance rs150042478 GRCh37 Chromosome 3, 113858379: 113858379
7 DRD3 NM_000796.5(DRD3): c.302T> G (p.Ile101Ser) single nucleotide variant Uncertain significance rs886057789 GRCh38 Chromosome 3, 114159836: 114159836
8 DRD3 NM_000796.5(DRD3): c.302T> G (p.Ile101Ser) single nucleotide variant Uncertain significance rs886057789 GRCh37 Chromosome 3, 113878683: 113878683
9 DRD3 NM_000796.5(DRD3): c.821G> A (p.Gly274Glu) single nucleotide variant Uncertain significance rs200825904 GRCh38 Chromosome 3, 114131303: 114131303
10 DRD3 NM_000796.5(DRD3): c.821G> A (p.Gly274Glu) single nucleotide variant Uncertain significance rs200825904 GRCh37 Chromosome 3, 113850150: 113850150
11 DRD3 NM_000796.5(DRD3): c.-105G> A single nucleotide variant Likely benign rs36211802 GRCh38 Chromosome 3, 114178726: 114178726
12 DRD3 NM_000796.5(DRD3): c.-105G> A single nucleotide variant Likely benign rs36211802 GRCh37 Chromosome 3, 113897573: 113897573
13 DRD3 NM_000796.5(DRD3): c.-252C> T single nucleotide variant Likely benign rs36211803 GRCh38 Chromosome 3, 114178873: 114178873
14 DRD3 NM_000796.5(DRD3): c.-252C> T single nucleotide variant Likely benign rs36211803 GRCh37 Chromosome 3, 113897720: 113897720
15 DRD3 NM_000796.5(DRD3): c.-281A> G single nucleotide variant Uncertain significance rs199852439 GRCh38 Chromosome 3, 114178902: 114178902
16 DRD3 NM_000796.5(DRD3): c.-281A> G single nucleotide variant Uncertain significance rs199852439 GRCh37 Chromosome 3, 113897749: 113897749
17 DRD3 NM_000796.5(DRD3): c.-286A> C single nucleotide variant Likely benign rs190248679 GRCh38 Chromosome 3, 114178907: 114178907
18 DRD3 NM_000796.5(DRD3): c.-286A> C single nucleotide variant Likely benign rs190248679 GRCh37 Chromosome 3, 113897754: 113897754
19 DRD3 NM_000796.5(DRD3): c.270+14A> G single nucleotide variant Uncertain significance rs75091114 GRCh38 Chromosome 3, 114171709: 114171709
20 DRD3 NM_000796.5(DRD3): c.270+14A> G single nucleotide variant Uncertain significance rs75091114 GRCh37 Chromosome 3, 113890556: 113890556
21 DRD3 NM_000796.5(DRD3): c.-114A> G single nucleotide variant Uncertain significance rs886057790 GRCh38 Chromosome 3, 114178735: 114178735
22 DRD3 NM_000796.5(DRD3): c.-114A> G single nucleotide variant Uncertain significance rs886057790 GRCh37 Chromosome 3, 113897582: 113897582
23 DRD3 NM_000796.5(DRD3): c.-153T> G single nucleotide variant Uncertain significance rs200345655 GRCh38 Chromosome 3, 114178774: 114178774
24 DRD3 NM_000796.5(DRD3): c.-153T> G single nucleotide variant Uncertain significance rs200345655 GRCh37 Chromosome 3, 113897621: 113897621
25 DRD3 NM_000796.5(DRD3): c.-318C> T single nucleotide variant Uncertain significance rs201561838 GRCh38 Chromosome 3, 114178939: 114178939
26 DRD3 NM_000796.5(DRD3): c.-318C> T single nucleotide variant Uncertain significance rs201561838 GRCh37 Chromosome 3, 113897786: 113897786
27 DRD3 NM_000796.5(DRD3): c.1151C> A (p.Thr384Asn) single nucleotide variant Uncertain significance rs886057788 GRCh38 Chromosome 3, 114128768: 114128768
28 DRD3 NM_000796.5(DRD3): c.1151C> A (p.Thr384Asn) single nucleotide variant Uncertain significance rs886057788 GRCh37 Chromosome 3, 113847615: 113847615
29 DRD3 NM_000796.5(DRD3): c.1077C> T (p.His359=) single nucleotide variant Uncertain significance rs3732791 GRCh38 Chromosome 3, 114128842: 114128842
30 DRD3 NM_000796.5(DRD3): c.1077C> T (p.His359=) single nucleotide variant Uncertain significance rs3732791 GRCh37 Chromosome 3, 113847689: 113847689
31 DRD3 NM_000796.5(DRD3): c.987A> G (p.Gln329=) single nucleotide variant Likely benign rs61735073 GRCh38 Chromosome 3, 114131137: 114131137
32 DRD3 NM_000796.5(DRD3): c.987A> G (p.Gln329=) single nucleotide variant Likely benign rs61735073 GRCh37 Chromosome 3, 113849984: 113849984
33 DRD3 NM_000796.5(DRD3): c.720A= (p.Gln240=) single nucleotide variant Likely benign rs2251177 GRCh38 Chromosome 3, 114139503: 114139503
34 DRD3 NM_000796.5(DRD3): c.720A= (p.Gln240=) single nucleotide variant Likely benign rs2251177 GRCh37 Chromosome 3, 113858350: 113858350
35 DRD3 NM_000796.5(DRD3): c.383+7C> T single nucleotide variant Uncertain significance rs200206712 GRCh38 Chromosome 3, 114159748: 114159748
36 DRD3 NM_000796.5(DRD3): c.383+7C> T single nucleotide variant Uncertain significance rs200206712 GRCh37 Chromosome 3, 113878595: 113878595
37 DRD3 NM_000796.5(DRD3): c.51A> G (p.Ala17=) single nucleotide variant Likely benign rs3732783 GRCh38 Chromosome 3, 114171942: 114171942
38 DRD3 NM_000796.5(DRD3): c.51A> G (p.Ala17=) single nucleotide variant Likely benign rs3732783 GRCh37 Chromosome 3, 113890789: 113890789
39 DRD3 NM_000796.5(DRD3): c.-38A> C single nucleotide variant Uncertain significance rs201872343 GRCh38 Chromosome 3, 114178659: 114178659
40 DRD3 NM_000796.5(DRD3): c.-38A> C single nucleotide variant Uncertain significance rs201872343 GRCh37 Chromosome 3, 113897506: 113897506
41 DRD3 NM_000796.5(DRD3): c.-333G> A single nucleotide variant Likely benign rs36212175 GRCh38 Chromosome 3, 114178954: 114178954
42 DRD3 NM_000796.5(DRD3): c.-333G> A single nucleotide variant Likely benign rs36212175 GRCh37 Chromosome 3, 113897801: 113897801
43 DRD3 NM_000796.5(DRD3): c.-388T> A single nucleotide variant Uncertain significance rs886057791 GRCh38 Chromosome 3, 114179009: 114179009
44 DRD3 NM_000796.5(DRD3): c.-388T> A single nucleotide variant Uncertain significance rs886057791 GRCh37 Chromosome 3, 113897856: 113897856

Expression for Essential Tremor

Search GEO for disease gene expression data for Essential Tremor.

Pathways for Essential Tremor

Pathways related to Essential Tremor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.97 FMR1 LINGO1 LRRK2 PRKN SLC1A2 SNCA
2 10.95 HTRA2 LRRK2 PRKN SLC6A3 SNCA
3 10.84 PRKN SLC6A3 SNCA

GO Terms for Essential Tremor

Cellular components related to Essential Tremor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth cone GO:0030426 9.65 FMR1 LRRK2 SNCA
2 perikaryon GO:0043204 9.63 FMR1 FUS LRRK2
3 presynapse GO:0098793 9.58 FMR1 PRKN SNCA
4 neuron projection GO:0043005 9.55 FMR1 LRRK2 PRKN SLC6A3 TENM4
5 postsynapse GO:0098794 9.54 FMR1 LRRK2 SNCA
6 inclusion body GO:0016234 9.43 LRRK2 SNCA
7 mitochondrial intermembrane space GO:0005758 9.43 CHCHD2 HTRA2 SNCA
8 neuronal cell body GO:0043025 9.35 FMR1 FUS LRRK2 SLC6A3 SNCA
9 dopaminergic synapse GO:0098691 9.32 DRD3 SLC6A3
10 axon GO:0030424 9.02 FMR1 LRRK2 SLC1A2 SLC6A3 SNCA

Biological processes related to Essential Tremor according to GeneCards Suite gene sharing:

(show all 28)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.91 DRD3 SLC1A2 SLC6A3 SNCA
2 locomotory behavior GO:0007626 9.76 DRD3 PRKN SLC6A3
3 cellular response to oxidative stress GO:0034599 9.75 HTRA2 LRRK2 SNCA
4 negative regulation of protein phosphorylation GO:0001933 9.72 LRRK2 PRKN SNCA
5 adult locomotory behavior GO:0008344 9.69 HTRA2 PRKN SNCA
6 mitochondrion organization GO:0007005 9.67 CHCHD2 HTRA2 LRRK2 PRKN
7 regulation of reactive oxygen species metabolic process GO:2000377 9.64 PRKN SNCA
8 behavioral response to cocaine GO:0048148 9.63 DRD3 SNCA
9 regulation of neuron death GO:1901214 9.63 LRRK2 SNCA
10 response to cocaine GO:0042220 9.63 DRD3 SLC6A3 SNCA
11 cellular protein catabolic process GO:0044257 9.62 HTRA2 PRKN
12 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.62 LRRK2 PRKN
13 positive regulation of proteasomal protein catabolic process GO:1901800 9.61 FMR1 PRKN
14 prepulse inhibition GO:0060134 9.6 DRD3 SLC6A3
15 cellular response to dopamine GO:1903351 9.59 LRRK2 PRKN
16 regulation of dopamine secretion GO:0014059 9.58 DRD3 PRKN SNCA
17 dopamine biosynthetic process GO:0042416 9.57 SLC6A3 SNCA
18 regulation of dopamine metabolic process GO:0042053 9.56 PRKN SLC6A3
19 cellular response to manganese ion GO:0071287 9.54 LRRK2 PRKN
20 protein localization to mitochondrion GO:0070585 9.52 LRRK2 PRKN
21 regulation of neurotransmitter secretion GO:0046928 9.5 FMR1 PRKN SNCA
22 dopamine uptake involved in synaptic transmission GO:0051583 9.49 PRKN SNCA
23 positive regulation of dopamine receptor signaling pathway GO:0060161 9.48 DRD3 LRRK2
24 regulation of synaptic vesicle transport GO:1902803 9.43 LRRK2 PRKN
25 synaptic transmission, dopaminergic GO:0001963 9.43 DRD3 PRKN SNCA
26 dopamine metabolic process GO:0042417 9.33 DRD3 PRKN SNCA
27 negative regulation of neuron death GO:1901215 9.26 HTRA2 LRRK2 PRKN SNCA
28 regulation of locomotion GO:0040012 8.8 DRD3 LRRK2 SNCA

Molecular functions related to Essential Tremor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.63 FMR1 FUS HTRA2 LRRK2 PRKN SNCA
2 dynein complex binding GO:0070840 9.26 FMR1 SNCA
3 phospholipase binding GO:0043274 8.96 PRKN SNCA
4 dopamine binding GO:0035240 8.62 DRD3 SLC6A3

Sources for Essential Tremor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....